GI Dynamics Gets FDA Conditional OK for a Trial of its EndoBarrier Obesity Treatment

August 23, 2012

GI Dynamics announced it has received conditional approval from the FDA to start a pivotal clinical trial of its EndoBarrier device for the treatment of patients who have uncontrolled Type 2 diabetes and who are obese.
Boston Globe

Adcomm Votes Down ALS Stem Cell Therapy, Debates Clinical Data vs. Personal Data

GI Dynamics Gets FDA Conditional OK for a Trial of its EndoBarrier Obesity Treatment

Upcoming Events

GMP Quality Management vSummit 2023: Where Quality Meets Risk

MAGI@home Clinical Research Conference 2023

FDA in 2024: What to Expect in an Election Year

How UDI and UDI Data Can — and Must — Be Used for More Than Just Device Identification

18th Annual FDA Inspections vSummit

Featured Products

FDA, FTC and DOJ Enforcement of Medical Device Regulations

Using Real-World Evidence in Drug and Device Submissions

Featured Stories

Adcomm Votes Down ALS Stem Cell Therapy, Debates Clinical Data vs. Personal Data

Reports Allege Philips Withheld Evidence of Ventilator Malfunctions for 11 Years

Summary Judgment Sought by Boehringer Ingelheim in its IRA Lawsuit

FDA Proposes New Rule on Who has Oversight on Lab Tests

The Revised ICH E8: A Guide to New Clinical Trial Requirements